<?xml version="1.0" encoding="UTF-8"?>
<p id="par0025">In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as responsible for the coronavirus disease 2019 (COVID-19) outbreak that started in China (
 <xref rid="bib0080" ref-type="bibr">Zhu et al., 2020</xref>). Treatment options investigated during previous severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics, both caused by other viruses of the 
 <italic>Betacoronavirus</italic> genus (SARS-CoV-1 and MERS-CoV, respectively), have been proposed as possible therapeutic agents for SARS-CoV-2, with controversial results. These agents include ribavirin and interferon alpha 2b (IFNÎ±-2b) (
 <xref rid="bib0050" ref-type="bibr">Martinez, 2020</xref>), lopinavir/ritonavir (
 <xref rid="bib0015" ref-type="bibr">Chu et al., 2004</xref>, 
 <xref rid="bib0005" ref-type="bibr">Arabi et al., 2020</xref>), and hydroxychloroquine (
 <xref rid="bib0060" ref-type="bibr">Savarino et al., 2006</xref>, 
 <xref rid="bib0010" ref-type="bibr">Chen et al., 2020</xref>, 
 <xref rid="bib0025" ref-type="bibr">Gautret et al., 2020</xref>, 
 <xref rid="bib0070" ref-type="bibr">Wang et al., 2020a</xref>).
</p>
